Resort at Squaw Creek Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2016



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

HIV Persistence: Pathogenesis and Eradication (X7)


Organizer(s) David M. Margolis, Satya Dandekar and Susana T. Valente
March 20—24, 2016
Resort at Squaw Creek • Olympic Valley, California USA
Discounted Abstract Deadline: Nov 19, 2015
Abstract Deadline: Dec 17, 2015
Scholarship Deadline: Nov 19, 2015
Discounted Registration Deadline: Jan 21, 2016

Sponsored by Gilead Sciences, Inc., Merck & Co., Inc. and Sangamo BioSciences, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Joint Meeting: HIV Vaccines (X8)

Summary of Meeting:
Despite the clinical success of antiretroviral therapy (ART), every day there are more people newly infected with HIV than those initiating ART. The complexities of dispensing lifelong ART for HIV-infected individuals make it imperative to develop strategies for HIV eradication, or at least to strictly control the virus without daily therapy. The clearance of a retroviral infection is a herculean task and requires unraveling the mechanisms of viral persistence and host immune interactions. Further, ART does not appear to completely mitigate the impact of HIV infection on human health, and a better understanding of the overt and subtle immune pathologies induced by HIV infection is needed. Recent studies of early therapeutic interventions and HIV-resistant cellular therapies have provided new insights into the development of HIV eradication strategies. The meeting will focus on all aspects of HIV persistence and eradication that include: (1) The understanding of persistent HIV infection; (2) Innate defenses against retroviral infection; (3) The interplay of the host inflammatory response and HIV pathogenesis; and (4) Novel concepts for viral eradication. Special attention will be paid to progress in the development of model systems to study latent infection as well as strategies to eradicate it. Emphasis will be placed on new, unpublished findings that will highlight novel insights and creative strategies to develop effective control and eradication of HIV infection.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, March 20 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 24 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 25 in order to fully experience the meeting.

SUNDAY, MARCH 20

16:00—20:00
Arrival and Registration

Lobby Alcove
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Cascades

MONDAY, MARCH 21

07:00—08:00
Breakfast

Cascades
08:00—09:00
Welcome and Keynote Address (Joint)
Meeting has ended...abstracts no longer viewable online.

Grand Sierra Ballroom
* David M. Margolis, University of North Carolina at Chapel Hill, USA

* Carl W. Dieffenbach, NIAID, National Institutes of Health, USA

Anthony S. Fauci, NIAID, National Institutes of Health, USA
Recorded Presentation: Ending the HIV/AIDS Pandemic: Follow the Science

09:00—11:30
Acute HIV Infection and Initial Transmission Events (Joint)
Meeting has ended...abstracts no longer viewable online.
This session aims to provide new information on the biology of HIV-1 transmission and the window of opportunity for intervention.

Grand Sierra Ballroom
* Nilu Goonetilleke, University of North Carolina at Chapel Hill, USA

George M. Shaw, University of Pennsylvania, USA
Novel SHIV Design to Recapitulate HIV-1 Transmission, Persistence and Pathogenesis and as a Guide for Vaccine and Cure Research

Joseph Eron, University of North Carolina School of Medicine, USA
Acute HIV Infection: Antiretroviral Therapy and Persistence

Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Switzerland
Novel Therapeutic Interventions in the Targeting of the HIV Cell Reservoir

Zachary S. Ende, Emory University, USA
Short Talk: Heterosexual Transmission of Subtype C HIV-1 Does Not Require Increased Replicative Capacity or Interferon Resistance

Shilpa Iyer, University of Pennsylvania, USA
Short Talk: Mucosal Transmission of HIV-1 Selects for Variants with Enhanced Infectivity, Replication Fitness and Interferon Resistance

09:40—10:00
Coffee Break

Sierra Prefunction
11:45—12:45
DAIDS Programmatic Agendas, Recent Review Policy Updates, and Grantsmanship Advice (Joint)
The workshop will consist of four presentations and a question and answer period at the end. Presentation topics: 1. The Persistence and Cure Agenda; 2. HIV Vaccine Initiatives; 3. Overview of Recent Policy Updates on Rigor and Reproducibly; and 4. Tips for Writing NIH Career (K) and Investigator Initiated (R01/R21) Grant Applications.

Grand Sierra Ballroom
11:30—13:00
Poster Setup

Alpine Ballroom
13:00—22:00
Poster Viewing

Alpine Ballroom
11:30—17:00
On Own for Lunch


Following Session is for HIV Vaccines (X8)

14:30—16:30
Workshop 1: Requirements for bnAb Induction

Grand Sierra Ballroom A-B
* Pamela J. Bjorkman, California Institute of Technology, USA

Matthew D. Gray, Fred Hutchinson Cancer Research Center, USA
Self-assembling HIV Envelope Nanoparticles Increase Antibody Binding, Membrane Dynamics and B-cell Activation

Christina Guzzo, NIAID, National Institutes of Health, USA
Critical Role of V2 Sulfotyrosines in Stabilizing the HIV-1 Envelope Trimer in Its Closed, Antibody-Protected Conformation

Colin Havenar-Daughton, La Jolla Institute of Allergy and Immunology, USA
Virtual Immunization with eOD-GT8: Probing the Human Naive B Cell Repertoire to a Candidate HIV Vaccine Immunogen

Cassandra Simonich, Fred Hutchinson Cancer Research Center, USA
An Infant bNAb with Low Somatic Hypermutation Contributes to Polyclonal Breadth

Lorena S. Ver, IAVI, International Aids Vaccine Initiative, USA
Characterization of Neutralizing Antibody Responses to the N332 Site of Vulnerability on HIV Env in IAVI Protocol C Cohort

Amelia Escolano, Rockefeller University, USA
Sequential Immunization Strategies to Elicit HIV-1 bNAbs in Human Ig Knock-in Mice

Daniela Fera, Boston Children's Hospital, Harvard Medical School, USA
Structural Analysis of an HIV-1 Broadly Neutralizing B-Cell Lineage Targeting the Env N332 Glycan

16:30—17:00
Coffee Available

Sierra Prefunction
17:00—19:15
Mechanisms of Persistent Infection
Meeting has ended...abstracts no longer viewable online.

Grand Sierra Ballroom C-D
* Steven G. Deeks, University of California, San Francisco, USA

Jonathan Karn, Case Western Reserve University, USA
Epigenetic Control of HIV Latency

Melanie M. Ott, University of California, San Francisco, USA
Epigenetic Regulation of HIV Latency

Susana T. Valente, Scripps Florida, USA
Eradication without Reactivation

Andrew P. Rice, Baylor College of Medicine, USA
Regulation of P-TEFb and HIV Latency


Following Session is for HIV Vaccines (X8)

17:00—19:15
Immunologic Correlates of Sterilizing Immunity
Meeting has ended...abstracts no longer viewable online.
This session will review what is know about the types of immune responses that have potential to prevent the acquisition of HIV-1 infection, with an emphasis on non-neutralizing antibodies.

Grand Sierra Ballroom A-B
* Mark Connors, NIAID, National Institutes of Health, USA

Merlin L. Robb, Walter Reed Army Institute of Research, USA
Optimizing Quality and Durability of Immune Responses: Insights from RV 144 Follow-up Studies

Genoveffa Franchini, NCI, National Institutes of Health, USA
Activated RAS in PBMCs and Extracellular Vesicle, Mucosal Envelope Antibody to V2, and Innate Lymphoid Cells are Associated with Vaccine-Mediated Reduced Risk of SIVmac251 Acquisition

Georgia D. Tomaras, Duke University Medical Center, USA
HIV-1 Vaccine Humoral Immunity, Immune Correlates and Mechanistic Insights

Genevieve Fouda, Duke University Medical Center, USA
Short Talk: HIV Exposed Infants Vaccinated with a rgp120/MF59 Vaccine have Higher Magnitude anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine

Thomas Musich, DHHS, National Institutes of Health, USA
Short Talk: Vaccine-Induced Effects on Neutrophils in Rhesus Macaques

19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Cascades/Alpine Ballroom
19:30—22:00
Poster Session 1

Alpine Ballroom

TUESDAY, MARCH 22

07:00—08:00
Breakfast

Cascades
08:00—11:15
Reservoirs and Persistence I
Meeting has ended...abstracts no longer viewable online.

Grand Sierra Ballroom C-D
* Susana T. Valente, Scripps Florida, USA

Janice E. Clements, Johns Hopkins University, USA
Tissue Reservoirs of CD4+T Cells and Macrophages in ART Suppressed SIV-Infected Macaques

Satya Dandekar, University of California, Davis, USA
Early Establishment of HIV Reservoirs

John M. Coffin, Tufts University, USA
Mechanism of HIV Persistence despite Suppressive Antiretroviral Therapy

J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, USA
In vivo Analysis of HIV Persistence

Sara Ferrando-Martinez, NIAID, National Institutes of Health, USA
Short Talk: Immune Activation Drives Accumulation of Follicular CTL during Chronic HIV/SIV Infection

Binhua Ling, Tulane National Primate Research Center, USA
Short Talk: Gut Viral Reservoirs in SIV-Infected Long-Term Nonprogressing Chinese Rhesus Macaques on Antiretroviral Therapy


Following Session is for HIV Vaccines (X8)

08:00—11:30
Epitopes, Structures and Ontogeny of Broadly Neutralizing Antibodies
Meeting has ended...abstracts no longer viewable online.
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.

Grand Sierra Ballroom A-B
* Rogier W. Sanders, Weill Medical College of Cornell University, USA

Pamela J. Bjorkman, California Institute of Technology, USA
Structure-Based Design of Improved Antibodies Against HIV

Sasha Murrell, The Scripps Research Institute, USA
Short Talk: Crystal Structures of Two Related Broadly Neutralizing Antibodies against the N332 Supersite in HIV Env

Marit van Gils, University of Amsterdam, Netherlands
Short Talk: Broadly Neutralizing Antibodies from an Elite Neutralizer Target a Novel Site at the gp120-gp41 Interface

Dennis R. Burton, The Scripps Research Institute, USA
Broadly Neutralizing Antibodies to Guide HIV Vaccine Design

Jinal Nomathemba Bhiman, National Institute for Communicable Diseases and WITS University, South Africa
Viral Variants that Initiate and Drive Maturation of Broadly Neutralizing Antibodies

William Schief, IAVI and The Scripps Research Institute, USA
Epitope-Focused HIV Vaccine Design

Christina Yacoob, Fred Hutchinson Cancer Research Center, USA
Short Talk: Selective Allelic Expansion of HIV-1 Immunized Rhesus Macaques Based on Different Antigenic Properties of Env Immunogens

09:20—09:40
Coffee Break

Sierra Prefunction
11:15—13:00
Poster Setup

Alpine Ballroom

Following Session is for HIV Vaccines (X8)

13:00—14:30
Hands-On Computer Session on Los Alamos Sequence Database
Shared computers will be supplied for the first 60 attendees. Interested participants may sign up for the meeting on a first-come, first-serve basis. If attendance is over 60 people you will be asked to bring your own computer.

Monument Peak
13:00—22:00
Poster Viewing

Alpine Ballroom
11:15—14:30
On Own for Lunch

14:30—16:30
Workshop 1: Challenges of Persistent HIV Infection

Grand Sierra Ballroom C-D
* Romas Geleziunas, Gilead Sciences, Inc., USA

Kirston M. Barton, University of Sydney, Australia
HIV-1 in the Blood and Intestine Contribute to Viremia During Treatment Interruption

Ya-Chi Ho, Johns Hopkins University School of Medicine, USA
Activation of Novel Splice Donor Sites Allows Production of tat and rev Transcripts in Defective Patient-Derived HIV-1 Proviruses

Lillian B. Cohn, Rockefeller University, USA
HIV DNA Integration Site Selection in Productive Infection

Allison Thomas, George Washington University, USA
After Long-Term ART, T-cell Responses Targeting Early HIV Proteins Uniquely Correlate with Infected Cell Frequencies

Luca Micci, Emory University, YNPRC, USA
Determinants of Viral Control following ART-interruption in SIV-infected Rhesus Macaques

James L. Riley, University of Pennsylvania, USA
Engineering Chimeric Antigen Receptors for Durable Control over HIV-1 Replication

Maud Mavigner, Emory University, USA
Reducing HIV Persistence by Targeting Stem Cell Properties of Memory CD4+ T-cells

Angela Wahl, University of North Carolina at Chapel Hill, USA
CD4+ Tissue-Resident Memory T Cells are an Important Reservoir for HIV Persistence

16:30—17:00
Coffee Available

Sierra Prefunction
17:00—19:00
Auxillary Genes and Host Restriction Factors
Meeting has ended...abstracts no longer viewable online.

Grand Sierra Ballroom C-D
* J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, USA

Alan N. Engelman, Dana-Farber Cancer Institute, USA
CPSF6 Regulates HIV-1 Integration into Active Chromatin

Stephen P. Goff, Columbia University, USA
Retroviral Silencing: Transcriptional and Post-Transcriptional Regulation

Michael Emerman, Fred Hutchinson Cancer Research Center, USA
Evolution of Host Antiviral Restriction Factors

Richard Apps, National Cancer Institute Frederick, USA
Short Talk: HIV-1 Immune Evasion by Downregulation of HLA-C


Following Session is for HIV Vaccines (X8)

17:00—19:15
Vaccine Concepts I
Meeting has ended...abstracts no longer viewable online.
This session will be in two parts and aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.

Grand Sierra Ballroom A-B
David C. Montefiori, Duke University Medical Center, USA
Standardized Assessments of HIV Vaccine-Elicited Neutralizing Antibodies

* Mario Roederer, NIAID, National Institutes of Health, USA
The SIV Model to Evaluate Antibody-Based Intervention

Bette T. Korber, Los Alamos National Laboratory, USA
Using Neutralization Resistance/Sensitivity Signatures to Inform Vaccine Design

Javier Guenaga, IAVI Neutralizing Antibody Center at TSRI, USA
Short Talk: Display of the HIV-1 Env MPER in the Context of a Well-ordered Soluble Uncleaved (NFL) Trimer

James Mark Binley, San Diego Biomedical Research Institute, USA
Short Talk: Eliciting Tier 2 anti-HIV-1 NAbs using Native, Membrane Trimers

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Cascades/Alpine Ballroom
19:30—22:00
Poster Session 2

Alpine Ballroom

WEDNESDAY, MARCH 23

07:00—08:00
Breakfast

Cascades
08:00—11:15
Antiviral Host Response and Inflammation
Meeting has ended...abstracts no longer viewable online.

Grand Sierra Ballroom C-D
* Satya Dandekar, University of California, Davis, USA

Nicolas Chomont, Université de Montréal, Canada
Immune Checkpoint Molecules and HIV Persistence during ART

Alberto Bosque, University of Utah, USA
Short Talk: Targeting Pathogen Recognition Receptors to Reactivate Latent HIV-1

Ivona Pandrea, University of Pittsburgh, USA
Nonhuman Primate Studies with Relevance for Cure Research

David Favre, GlaxoSmithKline, USA
Immune Modulation as a Strategy to Clear Persistent Infection

Heinrich Gottlinger, University of Massachusetts Medical School, USA
Short Talk: SERINC3 and SERINC5 Synergistically Inhibit HIV-1 Infectivity and are Antagonized by Nef

Catherine A. Blish, Stanford University School of Medicine, USA
Short Talk: NK Cell Response


Following Session is for HIV Vaccines (X8)

08:00—11:15
Pathways Leading to Long-Term Protective Immunity Against HIV-1
Meeting has ended...abstracts no longer viewable online.
This session aims to address the requirements for broadly neutralizing antibody induction at the cellular level.

Grand Sierra Ballroom A-B
* Jay A. Berzofsky, NCI, National Institutes of Health, USA

Bali Pulendran, Emory University, USA
Signaling Mechanisms

W. Ripley Ballou, GlaxoSmithKline Vaccines, USA
Inducing Long-Term Protection with Vaccines

Richard A. Koup, NIAID, National Institutes of Health, USA
T Cell Help

Maria Blasi, Duke University Medical Center, USA
Use of Integrase Defective Lentiviral Vectors Expressing HIV-Envs to Induce Durable Immune Responses

Jinghe Huang, NIAID, National Institutes of Health, USA
Short Talk: Intranasal Replication Competent Adenovirus Type 4-Influenza-H5 (Ad4-H5-Vtn) Vaccine Induces Durable Neutralizing Antibody Responses in Humans

Konstantin Virnik, Food and Drug Administration, USA
Short Talk: Expression of HIV and SIV Env Proteins in a Highly Immunogenic Rubella Vaccine Platform

09:20—09:40
Coffee Break

Sierra Prefunction
11:15—13:00
Poster Setup

Alpine Ballroom

Following Session is for HIV Vaccines (X8)

13:00—14:30
Hands-On Computer Session on Los Alamos Immunology Database
Shared computers will be supplied for the first 60 attendees. Interested participants may sign up for the meeting on a first-come, first-serve basis. If attendance is over 60 people you will be asked to bring your own computer.

Monument Peak
13:00—22:00
Poster Viewing

Alpine Ballroom
11:15—14:30
On Own for Lunch

14:30—16:30
Workshop 2: New Technologies and Approaches

Grand Sierra Ballroom C-D
* Karl Salzwedel, NIAID, National Institutes of Health, USA

Collin Kieffer, California Institute of Technology, USA
Longitudinal Imaging of Early HIV infection in Humanized Mice with Parallel 3D Immunofluorescence and Electron Microscopy

Bonnie J. Howell, Merck, USA
Ultrasensitive Detection of Viral p24 following Reactivation of Latent HIV

Tram N.Q. Pham, Institut de Recherches Cliniques de Montreal, Canada
Enhancing Tethering of HIV Virions by BST2/Tetherin Augments the Susceptibility of Productively and Latently Infected T Cells to ADCC Mediated by Broadly Neutralizing Anti-HIV Antibodies

Yik Lim Kok, University Hospital Zurich, Switzerland
A Novel HIV-1-Based Vector that Reproduces Features of Productive and Latent HIV-1 Infections

Julia Sung, University of North Carolina, USA
HIV specific Ex vivo Expanded T Cell (HXTC) Therapy to Target the Latent Reservoir

Kenneth M. Law, Icahn School of Medicine at Mount Sinai, USA
Cell-to-cell HIV-1 Transmission Promotes Multicopy Micro-Compartmentalized Infection in Humanized Mice

Lydie Trautmann, US Military HIV Research Program, USA
Differentiation of Effector CD8 T Cells Toward Short Lived Cells Lacking Memory Potential During Acute HIV Infection

Sarah DiNapoli, NIAID, National Institutes of Health, USA
Lymphoid Tissue-Resident Myeloid Cells Contain Replication-Competent Virus that is Genetically Similar to Virus from CD4+ T Cells in ARV-Naïve Asian Macaques

16:30—17:00
Coffee Available

Sierra Prefunction
17:00—19:00
Cure Studies in Models and Man
Meeting has ended...abstracts no longer viewable online.

Grand Sierra Ballroom C-D
* Carl W. Dieffenbach, NIAID, National Institutes of Health, USA

Daria J. Hazuda, Merck Research Laboratories, USA
HIV Latency Drug Discovery: Optimizing Drugs to Induce Latent HIV Expression

John W. Mellors, University of Pittsburgh School of Medicine, USA
Biomarkers of HIV Persistence and Response to Therapeutic Interventions

Jerome A. Zack, University of California, Los Angeles, USA
Synthetic PKC Modulators as HIV Latency Reversing Agents

Lucy Dorrell, University of Oxford, UK
Short Talk: Elimination of HIV-1 Reservoir Cells from Antiretroviral Therapy-Suppressed Subjects by Engineered Immune-Mobilising Dual Affinity T cell Receptors


Following Session is for HIV Vaccines (X8)

17:00—19:15
Vaccine Concepts II
Meeting has ended...abstracts no longer viewable online.
This is the second part of a two-part series that aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.

Grand Sierra Ballroom A-B
* Bette T. Korber, Los Alamos National Laboratory, USA

John P. Moore, Weill Medical College of Cornell University, USA
How to Make and Use Multiple Native-Like SOSIP Trimers for Vaccine and Structural Studies

Barton F. Haynes, Duke University Medical Center, USA
B Cell Lineage Immunogen Design Approach to Elicit HIV Broadly Neutralizing Antibodies

Peter D. Kwong, NIAID, National Institutes of Health, USA
Structure-Based Immunogen Design

Marzena Pazgier, Institute of Human Virology, USA
Short Talk: Paring down HIV-1 Env: Design and Structure of an Independent Inner Domain of gp120 Stably Expressing the A32 ADCC Epitope Sub-region

Talar Tokatlian, Massachusetts Institute of Technology, USA
Short Talk: Design and Characterization of gp140 Envelope Trimer-Coupled Liposomes for an HIV Vaccine

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Cascades/Alpine Ballroom
19:30—22:00
Poster Session 3

Alpine Ballroom

THURSDAY, MARCH 24

07:00—08:00
Breakfast

Cascades
07:30—08:00
Poster Setup

Alpine Ballroom
08:00—15:00
Poster Viewing

Alpine Ballroom
08:00—08:45
Keynote Address (Joint)
Meeting has ended...abstracts no longer viewable online.

Grand Sierra Ballroom
* David C. Montefiori, Duke University Medical Center, USA

John R. Mascola, NIAID, National Institutes of Health, USA
Active and Passive Antibody-Based Immunity to HIV-1

08:45—11:45
Immunotherapy (Joint)
Meeting has ended...abstracts no longer viewable online.
This session aims to address the potential value of antibodies in the treatment and cure of HIV-1 infection.

Grand Sierra Ballroom
* Michael Seaman, Beth Israel Deaconess Medical Center-Harvard Medical School, USA

David Ho, Aaron Diamond AIDS Research Center, USA
Bispecific Antibodies

Michael Farzan, The Scripps Research Institute, USA
AAV-Expressed eCD4-Ig as an Alternative HIV-1 Vaccine

David M. Margolis, University of North Carolina at Chapel Hill, USA
Enlisting Effector Cells to Clear Latent HIV Infection

Louis J. Picker, Oregon Health & Science University, USA
CMV-Based HIV Vaccines for HIV Prevention and Clearance

09:30—09:50
Coffee Break

Sierra Prefunction
11:45—12:45
Lunch

Cascades
12:00—14:30
Poster Session 4

Alpine Ballroom

Following Session is for HIV Vaccines (X8)

14:30—16:30
Workshop 2: NHP Models for HIV Vaccines

Grand Sierra Ballroom A-B
* Diane L. Bolton, US Military HIV Research Program, WRAIR, USA

Nina Rafterman Derby, Population Council, USA
HSV-2 Infection Increases Rectal SIV?Nef Infection and May Reduce Vaccine Effect

Shelby O'Connor, University of Wisconson-Madison, USA
Tracking SIV Infection and Viral Evolution in vivo using a Barcoded Virus Stock

Hadia Mohammad Abdelaal, University of Minnesota, USA
CTL-Based Vaccine-Induced Protection is Associated with Induction of High Follicular to Extra-Follicular Ratios of Virus-Specific CD8 T Cells

Namal Liyanage, NCI, National Institutes of Health, USA
Recruitment of Vaccine Induced MMucosal IL17+NKp44+Innate Lymphoid Cells (ILCs) to Decrease the Risk of SIVmac251 Acquisition in Macaques

M. Anthony Moody, Duke University Medical Center, USA
Vaccine-Induced Anatomic Distribution of Env-Specific B Cell Repertoires: Implications for the Genesis of Induced Mucosal Antibodies in Rhesus Macaques

George M. Shaw, University of Pennsylvania, USA

Jay A. Berzofsky, NCI, National Institutes of Health, USA
Immune Activation and the Microbiome in Mucosal Transmission of SHIV

Donald Forthal, University of California, Irvine, USA
Non-Neutralizing Antibodies Reduce the Rate of SIVmac251 Infection Following Low-Dose Repeated Penile Challenge

16:30—17:00
Coffee Available

Sierra Prefunction
17:00—18:45
Reservoirs and Persistence II
Meeting has ended...abstracts no longer viewable online.

Grand Sierra Ballroom C-D
* Douglas D. Richman, University of California, San Diego, USA

Sarah E. Palmer, University of Sydney, Australia
Characterizing the HIV-1 Reservoir During Long-Term Therapy

Vicente Planelles, University of Utah, USA
Novel Classes of HIV Latency-Reversing Agents

Nancie M. Archin, University of North Carolina, Chapel Hill, USA
Updates on in vivo Administration of Vorinostat


Following Session is for HIV Vaccines (X8)

17:00—18:45
Bridging Innate and Acquired Immunity
Meeting has ended...abstracts no longer viewable online.
This session aims to emphasize the potential importance of non-neutralizing antibodies and their mechanisms.

Grand Sierra Ballroom A-B
* Nicole Frahm, Fred Hutchinson Cancer Research Center, USA

Stylianos Bournazos, Rockefeller University, USA
Optimizing Antibody-FcR Interactions

Margaret Ellen Ackerman, Dartmouth College, USA
Profiling Protective Antibody Responses

George K. Lewis, University of Maryland, USA
Qualitative and Quantitative Variables that Contribute to Fc-mediated Protection Against HIV-1

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Grand Sierra Ballroom C-D

Following Session is for HIV Vaccines (X8)

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Grand Sierra Ballroom A-B
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Cascades/Alpine Ballroom
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Cascades/Alpine Ballroom

FRIDAY, MARCH 25

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Bill & Melinda Gates Foundation Gilead Sciences, Inc.
Merck & Co., Inc. Sangamo BioSciences, Inc.

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI123008-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Merck & Co., Inc.


Merck Research Laboratories


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676